Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
Tomtebodavägen 23A, Solna
SE-112 76 Stockholm
Swedish Orphan Biovitrum AB (Sobi) is a leading European specialty pharmaceutical company focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. It is the vision of Sobi to be an exciting and leading international rare disease pharmaceutical company.
The Dutch biotechnology company, Pharming Group NV has developed the first recombinant C1 inhibitor therapy (RUCONEST), which is approved for the treatment of acute HAE attacks in the EU, USA and Israel. RUCONEST is distributed directly in Germany, Austria, and the Netherlands by Pharming and in the rest of the EU by Swedish Orphan Biovitrum AB (Sobi). In the USA, Pharming has a partnership with Salix Pharmaceuticals to market this therapy.
RUCONEST is a non-blood derived human C1 inhibitor that is made in rabbits. Clinical trials have shown that RUCONEST is a safe and effective treatment for acute HAE attacks.